drugset / Trial / NCT05116800
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open label, two-stratum, phase 2 clinical trial evaluating the efficacy of 9-ING-41 in combination with gemcitabine/docetaxel in patients ≥10 years of age with advanced sarcoma. 9-ING-41 in combination with gemcitabine and docetaxel will lead to sustained disease control and/or increase the rates of objective response in patients with unresectable or metastatic soft tissue and bone sarcomas.
Timeline
- Start
- 2022-03-01
- Primary completion
- 2025-08-01
- Completion
- 2030-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elraglusib | Small molecule | 9.3 mg/kg | — |
| Background | Docetaxel | Small molecule | 75 mg/m2 | — |
| Background | Gemcitabine | Small molecule | 900 mg/m2 | — |